Sano Takeshi, Coit Daniel G, Kim Hyung Ho, Roviello Franco, Kassab Paulo, Wittekind Christian, Yamamoto Yuko, Ohashi Yasuo
Department of Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.
Gastric Cancer. 2017 Mar;20(2):217-225. doi: 10.1007/s10120-016-0601-9. Epub 2016 Feb 20.
The current AJCC staging system for gastric cancer (AJCC7) incorporated several major revisions to the previous edition. The T and N categories and the stage groups were newly defined, and adenocarcinoma of the esophagogastric junction (EGJ) was reclassified and staged according to the esophageal system. Studies to validate these changes showed inconsistent results. The International Gastric Cancer Association (IGCA) launched a project to support evidence-based revisions to the next edition of the AJCC staging system.
Clinical and pathological data on patients who underwent curative gastrectomy at 59 institutions in 15 countries between 2000 and 2004 were retrospectively collected. Patients lost to follow-up within 5 years of surgery were excluded. Patients treated with neoadjuvant therapy were excluded. The data were analyzed in total, and separately by region of treatment.
Of 25,411 eligible cases, 84.8 % were submitted from 24 institutions of Japan and Korea, 6.4 % from other Asian countries, and 8.8 % from 29 Western institutions. The T and N categories of AJCC7 clearly stratified the patient survival. Patients with pN3a and pN3b showed distinct prognosis in all regions, and by introducing pN3a and pN3b into a cluster analysis, we established a new stage grouping with better stratification than AJCC7, especially among stage III subgroups. Survival of Siewert type 2 and 3 EGJ tumors was better stratified by this IGCA stage grouping than by either esophageal or gastric scheme of AJCC7.
For the next revision of AJCC classification, we propose a new stage grouping based on a large, worldwide data collection.
当前的美国癌症联合委员会(AJCC)胃癌分期系统(AJCC7)对前一版进行了多项重大修订。重新定义了T和N分类以及分期组,食管胃交界(EGJ)腺癌根据食管系统重新分类和分期。验证这些变化的研究结果不一致。国际胃癌协会(IGCA)发起了一个项目,以支持对AJCC分期系统下一版进行基于证据的修订。
回顾性收集了2000年至2004年间在15个国家的59个机构接受根治性胃切除术患者的临床和病理数据。排除了术后5年内失访的患者。排除接受新辅助治疗的患者。对数据进行了总体分析,并按治疗地区分别分析。
在25411例符合条件的病例中,84.8%来自日本和韩国的24个机构,6.4%来自其他亚洲国家,8.8%来自29个西方机构。AJCC7的T和N分类清晰地对患者生存进行了分层。pN3a和pN3b患者在所有地区均显示出明显不同的预后,通过将pN3a和pN3b纳入聚类分析,我们建立了一个新的分期组,其分层比AJCC7更好,尤其是在III期亚组中。与AJCC7的食管或胃癌分期方案相比,IGCA分期组对Siewert 2型和3型EGJ肿瘤的生存分层更好。
对于AJCC分类的下一版修订,我们基于大规模的全球数据收集提出了一个新的分期组。